Literature DB >> 23997011

Timing of diagnosis of patients with Pompe disease: data from the Pompe registry.

Priya S Kishnani1, Hernán M Amartino, Christopher Lindberg, Timothy M Miller, Amanda Wilson, Joan Keutzer.   

Abstract

Diagnostic delays in Pompe disease are common. The diagnostic gap (the time from the onset of symptoms to the diagnosis of Pompe disease) and factors associated with diagnostic delays were examined among Pompe Registry patients in three onset categories: Group A, onset ≤12 months of age with cardiomyopathy; Group B, onset ≤12 months without cardiomyopathy and onset >12 months to ≤12 years; and Group C, onset >12 years. Of 1,003 patients, 647 were available for analysis. In all groups, musculoskeletal signs and symptoms were among the most frequent presenting signs and symptoms, in addition to cardiomyopathy in Group A, which was part of the group's definition. Diagnostic gaps existed in all three groups. Patients presenting with respiratory and musculoskeletal signs and symptoms concurrently had the shortest diagnostic gap, while those presenting with neither respiratory nor musculoskeletal signs and symptoms had the longest. Independent factors influencing the probability of a long diagnostic gap included presenting signs and symptoms (all three groups) and year of diagnosis and age at symptom onset (Groups B and C). Group B, which represents the infantile patients without cardiomyopathy and juvenile Pompe cases, had the longest median gap (12.6 years). Diagnostic testing methods used also were reviewed. Despite the availability of blood-based assays that can be used to quickly and accurately diagnose Pompe disease, diagnostic gaps in Pompe patients across the disease spectrum continue.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Pompe disease; blood-based assays; diagnosis; diagnostic delay; lysosomal storage disorder; registry; symptoms

Mesh:

Year:  2013        PMID: 23997011     DOI: 10.1002/ajmg.a.36110

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  33 in total

Review 1.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Authors:  Mugdha V Rairikar; Laura E Case; Lauren A Bailey; Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-09-19       Impact factor: 4.797

3.  Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Authors:  Claudio Semplicini; Pascaline Letard; Marie De Antonio; Nadjib Taouagh; Barbara Perniconi; Françoise Bouhour; Andoni Echaniz-Laguna; David Orlikowski; Sabrina Sacconi; Emmanuelle Salort-Campana; Guilhem Solé; Fabien Zagnoli; Dalil Hamroun; Roseline Froissart; Catherine Caillaud; Pascal Laforêt
Journal:  J Inherit Metab Dis       Date:  2018-08-28       Impact factor: 4.982

4.  Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.

Authors:  Jin-Sung Park; Hye-Gyung Kim; Jin-Hong Shin; Young-Chul Choi; Dae-Seong Kim
Journal:  Neurol Sci       Date:  2014-11-12       Impact factor: 3.307

5.  Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness.

Authors:  Zoltan Lukacs; Paulina Nieves Cobos; Stephan Wenninger; Tracey A Willis; Michela Guglieri; Marc Roberts; Rosaline Quinlivan; David Hilton-Jones; Teresinha Evangelista; Stephan Zierz; Beate Schlotter-Weigel; Maggie C Walter; Peter Reilich; Thomas Klopstock; Marcus Deschauer; Volker Straub; Wolfgang Müller-Felber; Benedikt Schoser
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

6.  Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.

Authors:  Federica Montagnese; E Barca; O Musumeci; S Mondello; A Migliorato; A Ciranni; C Rodolico; P De Filippi; C Danesino; A Toscano
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

Review 7.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

8.  Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.

Authors:  Si Houn Hahn; David Kronn; Nancy D Leslie; Loren D M Pena; Pranoot Tanpaiboon; Michael J Gambello; James B Gibson; Richard Hillman; David W Stockton; John W Day; Raymond Y Wang; Kristina An Haack; Raheel Shafi; Susan Sparks; Yang Zhao; Catherine Wilson; Priya S Kishnani
Journal:  Genet Med       Date:  2018-03-22       Impact factor: 8.822

9.  Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA).

Authors:  Mary Curry; Rosángel Cruz; Lisa Belter; Mary Schroth; Megan Lenz; Jill Jarecki
Journal:  BMC Pediatr       Date:  2021-05-17       Impact factor: 2.125

10.  Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.

Authors:  Mrudu Herbert; Laura E Case; Mugdha Rairikar; Heidi Cope; Lauren Bailey; Stephanie L Austin; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2018-08-23       Impact factor: 4.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.